Cutera (NASDAQ:CUTR) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a report released on Tuesday.

Several other research analysts also recently issued reports on the company. Maxim Group reaffirmed a “hold” rating on shares of Cutera in a research note on Wednesday, November 8th. Zacks Investment Research downgraded Cutera from a “buy” rating to a “hold” rating in a research note on Tuesday, October 10th. Roth Capital lifted their price target on Cutera from $41.00 to $47.00 and gave the stock a “buy” rating in a research note on Tuesday, September 12th. Finally, TheStreet raised Cutera from a “c” rating to a “b” rating in a research note on Friday, August 18th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $37.33.

Shares of Cutera (NASDAQ:CUTR) traded up $2.10 during midday trading on Tuesday, hitting $47.00. 627,889 shares of the company’s stock traded hands, compared to its average volume of 149,909. The stock has a market cap of $628.83, a price-to-earnings ratio of 57.12, a P/E/G ratio of 1.93 and a beta of 0.53. Cutera has a 52 week low of $16.55 and a 52 week high of $47.40.

Cutera (NASDAQ:CUTR) last issued its earnings results on Tuesday, November 7th. The medical device company reported $0.42 EPS for the quarter, topping the consensus estimate of $0.08 by $0.34. The company had revenue of $38.17 million for the quarter, compared to analyst estimates of $34.82 million. Cutera had a net margin of 7.99% and a return on equity of 18.73%. The business’s revenue was up 26.1% on a year-over-year basis. During the same period in the previous year, the firm earned $0.12 EPS. equities analysts anticipate that Cutera will post 0.55 earnings per share for the current year.

In other news, EVP Larry Laber sold 1,700 shares of Cutera stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $42.15, for a total transaction of $71,655.00. Following the completion of the transaction, the executive vice president now owns 72,413 shares of the company’s stock, valued at approximately $3,052,207.95. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director David B. Apfelberg sold 1,000 shares of Cutera stock in a transaction on Friday, November 17th. The stock was sold at an average price of $42.55, for a total value of $42,550.00. Following the transaction, the director now directly owns 8,055 shares of the company’s stock, valued at approximately $342,740.25. The disclosure for this sale can be found here. Insiders have sold a total of 14,950 shares of company stock valued at $609,770 in the last ninety days. Corporate insiders own 3.30% of the company’s stock.

Hedge funds have recently made changes to their positions in the stock. Parallel Advisors LLC acquired a new position in Cutera in the 3rd quarter valued at about $117,000. Legal & General Group Plc raised its stake in Cutera by 69.6% in the 3rd quarter. Legal & General Group Plc now owns 3,600 shares of the medical device company’s stock valued at $149,000 after purchasing an additional 1,477 shares during the last quarter. Greenwood Capital Associates LLC acquired a new position in Cutera in the 3rd quarter valued at about $210,000. Dynamic Technology Lab Private Ltd acquired a new position in Cutera in the 3rd quarter valued at about $264,000. Finally, Mackenzie Financial Corp acquired a new position in Cutera in the 3rd quarter valued at about $277,000. 87.64% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This report was first posted by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://www.americanbankingnews.com/2017/12/12/cutera-cutr-raised-to-buy-at-bidaskclub.html.

About Cutera

Cutera, Inc is a medical device company. The Company is engaged in the design, development, manufacture, marketing and servicing of laser and other energy-based aesthetics systems for practitioners across the world. The Company offers products based on product platforms, such as enlighten, excel HR, truSculpt, excel V and xeo, each of which enables physicians and other practitioners to perform aesthetic procedures for customers.

Receive News & Ratings for Cutera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera and related companies with MarketBeat.com's FREE daily email newsletter.